LJP 1082

Drug Profile

LJP 1082

Alternative Names: LJP-1082

Latest Information Update: 10 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator La Jolla Pharmaceutical Company
  • Class Anticoagulants
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Antiphospholipid syndrome; Thrombosis

Most Recent Events

  • 30 May 2006 Suspended - Phase-I for Antiphospholipid syndrome in USA (unspecified route)
  • 30 May 2006 Suspended - Phase-I for Thrombosis in USA (unspecified route)
  • 17 Nov 2003 Data presented at the 67th Annual Scientific Meeing of the American College of Rheumatology and the 38th Annual Meeting Association of Rheumatology Health Professionals (ACR/ARHP-2003) have been added to the adverse events and pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top